Future Science Group
Browse
- No file added yet -

Supplementary Figure 1: Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points.docx

Download (60.24 kB)
figure
posted on 2021-11-09, 15:15 authored by Ernest Law, Roya Gavanji, Sarah WalshSarah Walsh, Anja Haltner, Rebecca McTavish, Chris Cameron

Supplementary Figure 1

Funding

Pfizer, Inc.

History

Usage metrics

    Journal of Comparative Effectiveness Research

    Categories

    Keywords

    Abemaciclibadvanced breast cancerhealth-related quality of lifeHER2-negativehormone receptor-positiveindirect treatment comparisonmatching-adjusted indirect comparisonPalbociclibpatient-reported outcomesquality of lifeCancer Therapy (excl. Chemotherapy and Radiation Therapy)

    Licence

    CC BY-NC-ND 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC